Skip to main content
OpenTrials
Completed

NCT Number: NCT04620096

MENstrual Symptom Tracking to Understand and Assess (Women) Living With Cystic Fibrosis

Cystic fibrosis (CF) affects men and women equally, but after the onset of puberty, women with CF have a lower life expectancy than men with CF. Despite these known differences, the link between CF symptom trends and the menstrual cycle remains critically understudied. To address this gap, this study will investigate changes in CF-specific symptoms among women with CF to evaluate whether and how they correlate with their menstrual cycle. Specifically, the investigators hope to examine whether CF-related symptoms change throughout the menstrual cycle, what the impact of those symptoms is on quality of life, and how feasible it is to use a period tracking app to track CF-related symptoms throughout the menstrual cycle. Investigators are asking women ages 18-45 with CF, who have regular menstrual cycles, to participate. Study procedures, including online surveys, period tracking, and interview, will take approximately 3 months.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cystic Fibrosis Congenital, Hereditary, and Neonatal Diseases and Abnormalities Digestive System Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Lung Diseases Pancreatic Diseases Respiratory Tract Diseases

Age range

18 year–45 year

Sex eligibility

Female

Study type

Observational

Primary location

University of Washington

Seattle, Washington, 98195, United States

About this study

To better understand the connection between cyclically driven hormone fluctuations and CF-related symptoms, the investigators propose an explanatory, sequential mixed methods study in which 80 menstruating women with CF will be asked to track their daily CF-related symptoms for three consecutive cycles. From this cohort, the investigators will ask up to 30 women with CF to participate in one semi-structured interview to gather information about the impact of cyclical CF symptoms upon women's daily lives and any strategies they use to manage them. This study uses innovative technology to track CF-specific symptoms with a smartphone app. The investigators' hypothesis is that subjective changes in clinical CF symptoms, including pulmonary and sinus (primary outcome), rheumatic, and gastrointestinal (secondary outcomes), will map onto the phases of the menstrual cycle and will be cyclical in nature; women will report alternative ways in which they manage their cyclical CF symptoms; and the period tracker app will be easy for women to use.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Females with CF, ages > or = 18 and < 46 years
  • Able to read, speak, and understand English
  • Have regular menstrual cycles between 21 and 35 days
  • If using oral contraceptive pills, patch, or vaginal ring, must have a monthly withdrawal bleed every 21-35 days
  • If on a genetic modulator, must be on steady dose for at least 3 months
  • Willing to document daily symptoms (or no symptoms) every day for up to four consecutive months
  • Has a functioning smartphone app with capability to load a "period tracking" app or, if no smartphone, is willing to complete a paper diary and mail to research team monthly
  • Currently resides within the United States

Exclusion criteria

  • Not regularly menstruating or no regular withdrawal bleed every 21-35 days (with or without hormonal contraception use)
  • Planning pregnancy at the start of, or any time during, the 3-month observation period
  • Planning to use a hormonal IUD, subdermal contraceptive implant (such as Nexplanon), or injectable contraceptive (such as Depo-Provera) at the start of, or any time during, the 3-month observation period
  • Women on the transplant list or what have had a lung transplant

Treatment and study plan

Primary outcomes

  1. Average change of Cystic Fibrosis-related pulmonary symptoms from baseline for each of the four phases of the menstrual cycle (menses, follicular, ovulation, and luteal)

    Time frame: 3 consecutive menstrual cycles (each cycle is 28 days) following enrollment

    Rating of Mild, Moderate, or Severe in the Clue smartphone app

  2. Average change of Cystic Fibrosis-related sinus symptoms from baseline for each of the four phases of the menstrual cycle (menses, follicular, ovulation, and luteal)

    Time frame: 3 consecutive menstrual cycles (each cycle is 28 days) following enrollment

    Rating of Mild, Moderate, or Severe in the Clue smartphone app

Secondary outcomes

  1. Average change of Cystic Fibrosis-related rheumatic symptoms from baseline for each of the four phases of the menstrual cycle (menses, follicular, ovulation, and luteal)

    Time frame: 3 consecutive menstrual cycles (each cycle is 28 days) following enrollment

    Rating of Mild, Moderate, or Severe in the Clue smartphone app

  2. Average change of Cystic Fibrosis-related gastrointestinal symptoms from baseline for each of the four phases of the menstrual cycle (menses, follicular, ovulation, and luteal)

    Time frame: 3 consecutive menstrual cycles (each cycle is 28 days) following enrollment

    Rating of Mild, Moderate, or Severe in the Clue smartphone app

Sponsors and collaborators

Lead sponsor

University of Washington

Other

Collaborators

  • Mount Sinai Hospital, New York
  • University of California, San Diego
  • University of Illinois at Chicago

Registry information

Acronym: MENSTRUAL

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Nov 6, 2020
Registry last updated
May 22, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.